Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Open access
Tiacci, Enrico, Park, Jae H., De Carolis, Luca, Chung, Stephen S., Broccoli, Alessandro, Scott, Sasinya, Zaja, Francesco, Devlin, Sean, Pulsoni, Alessandro, Chung, Young R., Cimminiello, Michele, Kim, Eunhee, Rossi, Davide, Stone, Richard M., Motta, Giovanna, Saven, Alan, Varettoni, Marzia, Altman, Jessica K., Anastasia, Antonella, Grever, Michael R., Ambrosetti, Achille, Rai, Kanti R., Fraticelli, Vincenzo, Lacouture, Mario E., Carella, Angelo M., Levine, Ross L., Leoni, Pietro, Rambaldi, Alessandro, Falzetti, Franca, Ascani, Stefano, Capponi, Monia, Martelli, Maria P., Park, Christopher Y., Pileri, Stefano A., Rosen, Neal, Foà, Robin, Berger, Michael F., Zinzani, Pier L., Abdel-Wahab, Omar, Falini, Brunangelo, Tallman, Martin S.·2015·New England Journal of Medicine

Abstract

BACKGROUND: BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues. METHODS: We conducted two phase 2, single-group, multicenter studies of vemurafenib (at a dose of 960 mg twice daily)--one in Italy and one in the United States. The therapy was administered for a median of 16 weeks in the Italian study and 18 weeks in the U.S. study. Primary end points were the complete response rate (in the Italian trial) and the overall response rate (in the U.S. trial). Enrollment was completed (28 patients) in the Italian trial in April 2013 and is still open (26 of 36 planned patients) in the U.S. trial. RESULTS: The overall response rates were 96% (25 of 26 patients who could be evaluated) after a median of 8 weeks in the Italian study and 100% (24 of 24) after a median of 12 weeks in the U.S. study. The rates of complete response were 35% (9 of 26 patients) and 42% (10 of 24) in the two trials, respectively. In the Italian trial, after a median follow-up of 23 months, the median relapse-free survival was 19 months among patients with a complete response and 6 months among those with a partial response; the median treatment-free survival was 25 months and 18 months, respectively. In the U.S. trial, at 1 year, the progression-free survival rate was 73% and the overall survival rate was 91%. Drug-related adverse events were usually of grade 1 or 2, and the events most frequently leading to dose reductions were rash and arthralgia or arthritis. Secondary cutaneous tumors (treated with simple excision) developed in 7 of 50 patients. The frequent persistence of phosphorylated ERK-positive leukemic cells in bone marrow at the end of treatment suggests bypass reactivation of MEK and ERK as a resistance mechanism. CONCLUSIONS: A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. (Funded by the Associazione Italiana per la Ricerca sul Cancro and others; EudraCT number, 2011-005487-13; ClinicalTrials.gov number NCT01711632.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1506583

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 348

Metadata

Authors
Tiacci, E., Park, J. H., De Carolis, L., Chung, S. S., Broccoli, A., Scott, S., Zaja, F., Devlin, S., Pulsoni, A., Chung, Y. R., Cimminiello, M., Kim, E., Rossi, D., Stone, R. M., Motta, G., Saven, A., Varettoni, M., Altman, J. K., Anastasia, A., Grever, M. R., Ambrosetti, A., Rai, K. R., Fraticelli, V., Lacouture, M. E., Carella, A. M., Levine, R. L., Leoni, P., Rambaldi, A., Falzetti, F., Ascani, S., Capponi, M., Martelli, M. P., Park, C. Y., Pileri, S. A., Rosen, N., Foà, R., Berger, M. F., Zinzani, P. L., Abdel-Wahab, O., Falini, B., & Tallman, M. S.
Venue
New England Journal of Medicine
Published
2015-10-29
Volume
373
Issue
18
Pages
1733-1747
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1441792155
Cited by
348
References
32
FWCI
18.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. https://app.cochat.ai/papers/10.1056/nejmoa1506583
The paper
Tiacci, E., Park, J. H., De Carolis, L., Chung, S. S., Broccoli, A., Scott, S., Zaja, F., Devlin, S., Pulsoni, A., Chung, Y. R., Cimminiello, M., Kim, E., Rossi, D., Stone, R. M., Motta, G., Saven, A., Varettoni, M., Altman, J. K., Anastasia, A., . . . Tallman, M. S. (2015). Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1506583

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.